CD19 and lymphoma: Trifunctional NKp46 engager molecules (hereafter referred to as CD19-NKp46-NKCE and CD20-NKp46-NKCE), coengaging CD16A and targeting either CD19 or CD20, have been demonstrated to promote efficient NK cell–mediated antitumor activity in several preclinical models of lymphoma (34).